<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391662</url>
  </required_header>
  <id_info>
    <org_study_id>BIBABRAX</org_study_id>
    <secondary_id>2014-003596-27</secondary_id>
    <nct_id>NCT02391662</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación de Oncología Médica del Hospital de Cruces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asociación de Oncología Médica del Hospital de Cruces</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer incidence is increasing with age and the likelihood of elderly suffering from cancer&#xD;
      is 1:3. Although many clinical trials include elderly patients, no results for this subgroup&#xD;
      of patients are available. Since there is no specific recommendations for treatment of&#xD;
      elderly patients with pancreatic cancer, treatment with gemcitabine alone is the treatment of&#xD;
      choice for these patients.&#xD;
&#xD;
      Single-agent gemcitabine is the current standard of care, but the addition of cytotoxic and&#xD;
      targeted agents to gemcitabine has almost invariably provided no significant survival&#xD;
      improvement.&#xD;
&#xD;
      Results obtained recently in the MPACT phase III clinical trial in patients with pancreatic&#xD;
      cancer treated with nab-paclitaxel combined with gemcitabine have shown improvement in&#xD;
      overall survival, but due to in this clinical trial was included patients between 27 and 88&#xD;
      years, it is considered necessary to conduct a specific study for patients over 70 years.&#xD;
&#xD;
      The aim of this study is to investigate whether the clinical benefit of nab-paclitaxel&#xD;
      associated with gemcitabine can be extended to elderly patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2015</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment through 3-months deterioration free rate</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The general deterioration of the patient is assessed with the EORTC-QLQ-C30 scale. t will be considered definitive deterioration a decrease of at least 10 points from baseline. We will evaluate the rate of patients free of definitive deterioration at 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety profile of gemcitabine and nab-paclitaxel, measured by Number of events per patient according to NCI-CTC-AE criteria</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of events per patient according to NCI-CTC-AE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>Time from patient inclusion to disease progression according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time from patient inclusion to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective radiographic response (ORR)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Response rate will be evaluated according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19.9 biomarker response</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>CA 19.9 biomarker response will be considered a decrease of at least 50% compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pancreatic Carcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel plus Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 &amp; 15 in a 28 days cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4</intervention_name>
    <description>Nab-paclitaxel 125 mg/m2 days 1,8 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Nab-paclitaxel plus Gemcitabine</arm_group_label>
    <other_name>Nab-paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine 1000 weeks 1,2,3/4</intervention_name>
    <description>Gemcitabine 1000 days 1,8 &amp; 15 in a 28 days cycle</description>
    <arm_group_label>Nab-paclitaxel plus Gemcitabine</arm_group_label>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically-confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          -  Stage IV disease (metastatic only)&#xD;
&#xD;
          -  No prior systemic therapy for their diagnosis (except in adjuvant setting &gt; six months&#xD;
             previously)&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Age &gt;=70 years.&#xD;
&#xD;
          -  Evidence of either or both of the following:&#xD;
&#xD;
               -  RECIST-defined measurable disease (lesions that can be accurately measured in at&#xD;
                  least one dimension with the longest diameter &gt;= 20mm using conventional&#xD;
                  techniques or &gt;= 10 mm with spiral CT scan)&#xD;
&#xD;
               -  An elevated serum CA19-9 at baseline ( &gt;= 2X ULN)&#xD;
&#xD;
          -  Female patients must be either surgically sterile or postmenopausal.&#xD;
&#xD;
          -  Male patients must be surgically sterile or must agree to use a condom during sex with&#xD;
             women who may become pregnant while receiving the study drug and for 6 months after&#xD;
             receiving the last dose.&#xD;
&#xD;
          -  Adequate bone marrow function:&#xD;
&#xD;
               -  ANC &gt;= 1500/uL&#xD;
&#xD;
               -  platelet count &gt;= 100,000/uL&#xD;
&#xD;
               -  hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Adequate hepatic function:&#xD;
&#xD;
               -  Total bilirubin &lt;= 1.5 X ULN&#xD;
&#xD;
               -  AST (SGOT) &lt;= 2.5 X ULN&#xD;
&#xD;
               -  ALT (SGPT) &lt;= 2.5 X ULN&#xD;
&#xD;
          -  Adequate renal function as determined by either:&#xD;
&#xD;
               -  Serum creatinine &lt;= 1.5 X ULN&#xD;
&#xD;
               -  Calculated or measured creatinine clearance &gt;= 40 mL/min (for calculated&#xD;
                  creatinine clearance, Cockroft-Gault equation will be used).&#xD;
&#xD;
          -  Ability to understand the nature of this study protocol and give written informed&#xD;
             consent&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior systemic or investigational therapy for metastatic pancreatic cancer.&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures.&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition&#xD;
             that, in the opinion of the investigator, renders the subject at high risk from&#xD;
             treatment complications or might affect the interpretation of the results of the&#xD;
             study.&#xD;
&#xD;
          -  Presence of central nervous system or brain metastases.&#xD;
&#xD;
          -  Life expectancy &lt; 12 weeks.&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation.&#xD;
&#xD;
          -  Prior malignancy except for adequately treated basal cell skin cancer, in situ&#xD;
             cervical cancer, adequately treated Stage I or II cancer from which the patient is&#xD;
             currently in complete remission, or any other form of cancer from which the patient&#xD;
             has been disease-free for 5 years.&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic&#xD;
             coronary artery disease and cardiac arrhythmias not well controlled with medication)&#xD;
             or myocardial infarction within the last 12 months.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption&#xD;
             syndrome.&#xD;
&#xD;
          -  Known, existing uncontrolled coagulopathy.&#xD;
&#xD;
          -  Pre-existing sensory neuropathy &gt; grade 1.&#xD;
&#xD;
          -  Major surgery within 4 weeks of the start of study treatment, without complete&#xD;
             recovery.&#xD;
&#xD;
          -  Concurrent/pre-existing use of anticoagulant treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo López Vivanco, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Cruces</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalari de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08240</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Gipuzkoa</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de La Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>San Cristóbal de La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. Hospitalario Universitario Insularmaterno-Infantil</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Hm Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Pancreatic Adenocarcinoma</keyword>
  <keyword>Elderly</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

